Imugene Limited (ASX:IMU)
0.2700
-0.0200 (-6.90%)
Sep 3, 2025, 4:10 PM AEST
Imugene Revenue
In the fiscal year ending June 30, 2025, Imugene had annual revenue of 4.40M AUD, down -11.53%. Imugene had revenue of 3.14M in the half year ending June 30, 2025, a decrease of -54.94%.
Revenue
4.40M
Revenue Growth
-11.53%
P/S Ratio
19.03
Revenue / Employee
879.36K
Employees
5
Market Cap
83.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 4.40M | -573.22K | -11.53% |
Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.79B |
Telix Pharmaceuticals | 1.01B |
Ansell | 3.06B |
Mesoblast | 26.23M |
Imugene News
- 7 weeks ago - Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL - PRNewsWire
- 7 weeks ago - Imugene set to dazzle market with new clinical data, cash call - The Australian Financial Review
- 1 year ago - Imugene Ltd Azer-cel Trial Update Transcript - GuruFocus
- 1 year ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 1 year ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 1 year ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 1 year ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 1 year ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire